Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

393 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.
Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, Waller EK, Jaglowski S, Bishop MR, Damon LE, Foley SR, Westin JR, Fleury I, Ho PJ, Mielke S, Teshima T, Janakiram M, Hsu JM, Izutsu K, Kersten MJ, Ghosh M, Wagner-Johnston N, Kato K, Corradini P, Martinez-Prieto M, Han X, Tiwari R, Salles G, Maziarz RT. Schuster SJ, et al. Among authors: corradini p. Lancet Oncol. 2021 Oct;22(10):1403-1415. doi: 10.1016/S1470-2045(21)00375-2. Epub 2021 Sep 10. Lancet Oncol. 2021. PMID: 34516954 Clinical Trial.
Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells.
Corradini P, Dodero A, Zallio F, Caracciolo D, Casini M, Bregni M, Narni F, Patriarca F, Boccadoro M, Benedetti F, Rambaldi A, Gianni AM, Tarella C. Corradini P, et al. J Clin Oncol. 2004 Jun 1;22(11):2172-6. doi: 10.1200/JCO.2004.12.050. J Clin Oncol. 2004. PMID: 15169805 Clinical Trial.
Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome.
Corradini P, Dodero A, Farina L, Fanin R, Patriarca F, Miceli R, Matteucci P, Bregni M, Scimè R, Narni F, Pogliani E, Locasciulli A, Milani R, Carniti C, Bacigalupo A, Rambaldi A, Bonifazi F, Olivieri A, Gianni AM, Tarella C; Gruppo Italiano Trapianto di Midollo Osseo. Corradini P, et al. Leukemia. 2007 Nov;21(11):2316-23. doi: 10.1038/sj.leu.2404822. Epub 2007 Jun 28. Leukemia. 2007. PMID: 17597807
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR; International Vidaza High-Risk MDS Survival Study Group. Fenaux P, et al. Lancet Oncol. 2009 Mar;10(3):223-32. doi: 10.1016/S1470-2045(09)70003-8. Epub 2009 Feb 21. Lancet Oncol. 2009. PMID: 19230772 Free PMC article. Clinical Trial.
Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up.
Björkstrand B, Iacobelli S, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Musto P, Beksac M, Bosi A, Milone G, Corradini P, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Gahrton G. Björkstrand B, et al. Among authors: corradini p. J Clin Oncol. 2011 Aug 1;29(22):3016-22. doi: 10.1200/JCO.2010.32.7312. Epub 2011 Jul 5. J Clin Oncol. 2011. PMID: 21730266
Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect.
Dodero A, Spina F, Narni F, Patriarca F, Cavattoni I, Benedetti F, Ciceri F, Baronciani D, Scimè R, Pogliani E, Rambaldi A, Bonifazi F, Dalto S, Bruno B, Corradini P. Dodero A, et al. Among authors: corradini p. Leukemia. 2012 Mar;26(3):520-6. doi: 10.1038/leu.2011.240. Epub 2011 Sep 9. Leukemia. 2012. PMID: 21904377 Free article.
Phase II study of sorafenib in patients with relapsed or refractory lymphoma.
Guidetti A, Carlo-Stella C, Locatelli SL, Malorni W, Pierdominici M, Barbati C, Mortarini R, Devizzi L, Matteucci P, Marchianò A, Lanocita R, Farina L, Dodero A, Tarella C, Di Nicola M, Corradini P, Anichini A, Gianni AM. Guidetti A, et al. Among authors: corradini p. Br J Haematol. 2012 Jul;158(1):108-19. doi: 10.1111/j.1365-2141.2012.09139.x. Epub 2012 May 10. Br J Haematol. 2012. PMID: 22571717 Free article. Clinical Trial.
Autologous stem cell transplantation for T-cell lymphomas.
Perrone G, Corradini P. Perrone G, et al. Among authors: corradini p. Semin Hematol. 2014 Jan;51(1):59-66. doi: 10.1053/j.seminhematol.2013.11.002. Epub 2013 Nov 14. Semin Hematol. 2014. PMID: 24468317 Review.
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, Corradini P, Chuncharunee S, Lee JJ, Schlossman RL, Shelekhova T, Yong K, Tan D, Numbenjapon T, Cavenagh JD, Hou J, LeBlanc R, Nahi H, Qiu L, Salwender H, Pulini S, Moreau P, Warzocha K, White D, Bladé J, Chen W, de la Rubia J, Gimsing P, Lonial S, Kaufman JL, Ocio EM, Veskovski L, Sohn SK, Wang MC, Lee JH, Einsele H, Sopala M, Corrado C, Bengoudifa BR, Binlich F, Richardson PG. San-Miguel JF, et al. Among authors: corradini p. Lancet Oncol. 2014 Oct;15(11):1195-206. doi: 10.1016/S1470-2045(14)70440-1. Epub 2014 Sep 18. Lancet Oncol. 2014. PMID: 25242045 Clinical Trial.
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial.
Rambaldi A, Grassi A, Masciulli A, Boschini C, Micò MC, Busca A, Bruno B, Cavattoni I, Santarone S, Raimondi R, Montanari M, Milone G, Chiusolo P, Pastore D, Guidi S, Patriarca F, Risitano AM, Saporiti G, Pini M, Terruzzi E, Arcese W, Marotta G, Carella AM, Nagler A, Russo D, Corradini P, Alessandrino EP, Torelli GF, Scimè R, Mordini N, Oldani E, Marfisi RM, Bacigalupo A, Bosi A. Rambaldi A, et al. Among authors: corradini p. Lancet Oncol. 2015 Nov;16(15):1525-1536. doi: 10.1016/S1470-2045(15)00200-4. Epub 2015 Sep 28. Lancet Oncol. 2015. PMID: 26429297 Free article. Clinical Trial.
393 results